Where Will Moderna Be in 5 Years?
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
Moderna Options Spot-On: On April 17th, 83,342 Contracts Were Traded, With 858.25K Open Interest
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years
Most Shorted S&P 500 Stocks in March
Short Bets Against S&P 500 Healthcare Stock Rises in March; MRNA Stays Top Shorted
Pfizer, GSK to Benefit as CDC Panel Endorses Wider Availability of RSV Shots
William Blair Maintains Moderna(MRNA.US) With Hold Rating
Leerink Partners Maintains Moderna(MRNA.US) With Sell Rating, Cuts Target Price to $23
Leerink Partners Sticks to Their Sell Rating for Moderna (MRNA)
Moderna Inc. Stock Slips 4.0%, Underperforms Competitors
Unusual Options Activity: FSLR, GOOGL and Others Attract Market Bets, FSLR V/OI Ratio Reaches 425.0
Moderna Options Spot-On: On April 16th, 98,123 Contracts Were Traded, With 856.91K Open Interest
Express News | US Cdc Advisers Recommend Rsv Vaccine for Adults 50-59 Years of Age Who Are at Increased Risk of Severe Rsv Disease
Top SA Quant-rated Healthcare Stocks as Q1 Earnings Unfold
Sell-rated S&P 500 Stocks as per Seeking Alpha's Quant Model
Moderna, Novavax Shares Dip as CDC Panel Suggests Limiting COVID Shot Updates
Express News | Shares of Moderna Down 1.2%, Novavax Down 1.3% Premarket
Express News | Shares of Some Vaccine Makers Down Premarket as US Cdc Advisers Discuss Narrowing Use of Covid-19 Booster Shots
Retail Buyers vs. Global Sellers: Is Now the Time to Jump into U.S. Stocks?